PubMed Health⌕ Search

Biomedical subjects

F Pupita

Publications and source records attributed to F Pupita.

At least 19 recordsLinked to original sources
PubMed1991

[Peripheral vascular damage in hypertension].

The authors relate the pathophysiologic, hemodynamic and pharmacologic aspects of peripheral vascular damage in arterial hypertension. Particular attention is paid to the role of structural and functional changes both large elastic and muscular arteries (macroangiopathy) and small resistance vessels (microangiopathy) in the determinism and maintenance of arterial hypertension. These changes include impaired arterial wall compliance, vascular hyperactivity to agonists due to both hypertrophy and hyperplasia of smooth muscle cells, and endothelial dysfunction seen as an increase in endothelial permeability as well as an impaired release of relaxing and contracting factors. In the second part, personal observations are related. The aim of the research was to individuate hemodynamic non invasive patterns of peripheral vascular damage in essential, mild or moderate, hypertensives and to evaluate the hemodynamic peripheral effect of hypotensive drugs. The hemodynamic evaluation has been carried out by means of epiaortic vessels and lower limbs echo-Doppler, strain gauge plethysmography of lower limbs, and echocardiography. The following parameters have been considered: Trevis index, rest flow, peak flow, total time, resistance index of Pourcelot, left ventricular mass and ejection fraction. The first study involved 100 subjects (60 males and 40 females) with mild or moderate hypertension and a control group of 60 healthy subjects (35 males and 25 females). The hypertensives, compared to normotensives, showed an increase of Trevis index, reduction of peak flow, increase of total time and increase of resistance index. The second study was performed on 60 hypertensive subjects, 28 (17 diabetics) treated with nicardipine slow-release (40 mg twice a day) and 32 treated with terazosine (2-4 mg once a day). The treatment with nicardipine slow-release showed an increase of Trevis index, increase of rest flow and reduction of resistance index; the left ventricular mass resulted reduced. The treatment with terazosine showed a significant increase of rest flow and peak flow, reduction of total time, increase of Trevis index, reduction of resistance index, reduction of left ventricular mass. These data, concordantly with what known in literature, showed in hypertension an hemodynamic situation characterized by high resistance circulations, expression of arteriolar involvement. Nicardipine and terazosine can be placed as first choice hypotensive drugs adding at the hypotensive efficacy and tolerability a positive effect on peripheral vascular damage.

Arteries↗
PubMed1990

[Clinical experience with an anticholinergic spasmolytic cimetropium bromide in the treatment of patients with renal colic].

We treated 38 consecutive outpatients with ureter colic with a new anticholinergic spasmolytic agent, cimetropium bromide, in order to evaluate its efficacy in this condition. After assessing pain intensity by means of a visual analogic scale, we administered 5 mg i.v. Already after 30 minutes, 4 patients (11%) reported complete subsidence of pain. In 21 patients (55%) pain subsided almost completely within one hour. Eighteen patients required a second 5 mg i.v. injection after one hour; of these, 13 (72%) had complete regression or marked reduction of pain. Apart from dryness of the mouth which appeared in two cases after the second injection and was of moderate intensity, no side effects were observed.

Acute Disease↗
PubMed1990

[The treatment of refractory hyperlipoproteinemias].

The authors have studied a group of 25 patients treated with an HMG-CoA reductase inhibitor associated with DEAE-dextran, a safe and useful drug for the treatment of dyslipidemia. The patients were selected from a group of subjects previously submitted to long-term treatment with an HMG-CoA reductase inhibitor only who had failed to achieve normal cholesterol blood levels. The combined treatment with DEAE-dextran (1.5 g 3 times daily) and simvastatin (20 mg once daily) for 90 days lead to a further significant decrease in cholesterol and triglyceride blood levels. These findings confirm the validity of the association of an ion exchange resin with an HMG-CoA reductase inhibitor in the treatment of refractory dyslipidemias.

Anticholesteremic Agents↗
PubMed1990

[A large case load of patients with dyslipidemia: effects of treatment with deae-dextran].

The authors report the results of an open trial in 859 dyslipidemic patients, performed with the cooperation of general practitioners, treated with isocaloric diet and daily doses of 3 g deae-dextran for 3 months. Deae-dextran was effective in reducing cholesterol and triglyceride blood levels and in controlling body weight. The drug was very well tolerated and no significant side effects were registered during treatment with deae-dextran.

Adult↗
PubMed1989

Treatment of patients with chronic airways obstruction: a controlled study with bamyphylline.

A single-blind, placebo-controlled study was carried out in 30 patients with chronic obstructive bronchopneumopathy to assess the effectiveness and tolerability of the theophylline derivative, bamyphylline. On entry, patients were allocated to receive twice daily oral doses of either 600 mg bamyphylline or placebo for a period of 60 days. Spirometric measurements, blood pressure and respiratory rate recordings and blood gas analyses were made at baseline and after 10, 30 and 60 days of treatment, as were assessments of clinical and objective signs, such as sibili, rales and vesicular murmurs. Plasma concentrations of bamyphylline 1 hour after the first dose of the day were monitored at the same intervals. The results showed that there was a highly significant progressive improvement in pulmonary function which was already apparent after 10 days and this was accompanied by a marked improvement in cardiac dynamics and clinical signs. Plasma concentrations of bamyphylline remained stable throughout the study period and there were no reports of side-effects or significant variations in blood chemistry.

Adult↗
PubMed1987

Investigation on the fate of orally administered DEAE-dextran in rats.

The breakdown of the carbohydrates by the colonic bacterial flora can cause intestinal symptoms, such as meteorism, abdominal pain and diarrhoea. The ability of digestive enzymes and colonic bacterial flora to break down the DEAE-dextran, a new lipid lowering resin, was investigated in rats. DEAE-dextran appeared to be unaffected by either enzyme activity in the small intestine or bacterial flora in the large intestine. This may be important when dealing with the pharmacological activity of DEAE-dextran and estimating its side effects. Small intestinal transit rate appeared to be accelerated by oral DEAE-dextran in rats.

Administration, Oral↗
PubMed1987

Evidence of a lack of enteric side-effects induced by DEAE-dextran in man.

The breakdown of the carbohydrates by the colonic bacterial flora can cause intestinal symptoms, such as meteorism, abdominal pain and diarrhoea. The ability of human bacterial flora to break down the DEAE-dextran, a new lipid lowering resin, similar to cholestyramine, was investigated in man. Colonic bacterial flora did not appear to break down DEAE-dextran, as assessed by hydrogen respiratory excretion measured in healthy volunteers. Furthermore, the blood levels of vitamin A, E and D (as 25-OH and 1,25-OH derivatives) were measured in patients treated with the DEAE-dextran in order to study the interference of DEAE-dextran on the absorption of liposoluble vitamins. With the exception of slightly depressed vitamin A levels in 3 patients out of 16, the blood values of the vitamins A, E and D were within the normal ranges, indicating that DEAE-dextran does not interfere with liposoluble vitamin absorption by the gut.

Adult↗
PubMed1987

Life quality in patients under hypotensive treatment.

The authors studied the life quality in a group of 74 patients--31 males and 43 females--affected with essential hypertension of World Health Organization I or II degree. All patients began treatment with frusemide at a dose of 25 mg once a day. The 35 non-responsive patients to frusemide were then treated, by random selection, with captopril at a dose of 25 mg twice a day, or nadolol at a dose of 80 mg once a day, for three months. The results show no significant differences on the hypotensive effect with either drug; in view of the incidence of side-effects of the two drugs, treatment with captopril is clearly better tolerated by the patients.

Antihypertensive Agents↗
PubMed1985

[Diuretics].

Explore the source record for details and available documents.

Aldosterone↗